FindTrial
Sign In

Rebastinib

DRUG3 trials

Sponsors

Montefiore Medical Center, Deciphera Pharmaceuticals, LLC

Conditions

Breast AdenocarcinomaBreast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastLocally Advanced or Metastatic Solid TumorRecurrent Breast CarcinomaStage IV Breast Cancer

Phase 1

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
TerminatedNCT02824575
Montefiore Medical CenterBreast Adenocarcinoma, Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast +2
Start: 2016-07-31End: 2021-12-27Updated: 2022-04-04
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
TerminatedNCT03601897
Deciphera Pharmaceuticals, LLCLocally Advanced or Metastatic Solid Tumor
Start: 2018-10-25End: 2022-05-23Updated: 2024-12-27
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
TerminatedNCT03717415
Deciphera Pharmaceuticals, LLCLocally Advanced or Metastatic Solid Tumor
Start: 2019-01-02End: 2022-11-01Updated: 2024-12-27

Related Papers

Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
Journal of Clinical Oncology2021-05-204 citations
An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.
Journal of Clinical Oncology2020-05-20
Abstract B055: Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors
Molecular Cancer Therapeutics2019-12-013 citations
An open label, multicenter, phase 1b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors.
Journal of Clinical Oncology2019-05-202 citations
Abstract BS1-1: High resolution intravital imaging of the mechanism of how breast cancer initiates and sustains systemic dissemination
Cancer Research2019-02-15
Abstract OT2-06-04: Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer
Cancer Research2018-02-15
Abstract CT040: Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer
Cancer Research2017-07-01
Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer (MBC).
Journal of Clinical Oncology2017-05-203 citations
A metastasis biomarker (MetaSite <i>Breast</i>™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.
PubMed2017-01-0185 citations